Eylea keeps its lead in the reti­nal space as physi­cians re­main hes­i­tant on Roche's Susvi­mo — re­port

Roche trum­pet­ed a “ma­jor ad­vance­ment” in the reti­nal space with the ap­proval of its eye drug Susvi­mo last Oc­to­ber, tout­ing it as a more man­age­able op­tion for pa­tients with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion. How­ev­er, safe­ty con­cerns leave some physi­cians hes­i­tant.

While most oph­thal­mol­o­gists have heard of Susvi­mo — 86%, ac­cord­ing to the lat­est Spher­ix sur­vey of 76 doc­tors — on­ly one in ten be­lieve the ben­e­fits com­plete­ly out­weigh the risks. And a ma­jor­i­ty of the re­spon­dents said they’d turn to Re­gen­eron’s Eylea as a safer and more ac­ces­si­ble op­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER